Acumen reports Q3 net loss $26.5M; cash $136.1M supports ops into early 2027

Acumen Pharmaceuticals, Inc.

2025-Q3 EPS reported -$1.59 vs consensus -$0.62 ▼ miss (-158.2%)

Cash, equivalents & marketable securities $136.1M at Sept 30, down from $166.2M at June 30; runway into early 2027.
Net loss $26.5M vs $29.8M YoY; R&D expense fell to $22.0M from $27.2M.
First patient dosed in November 2025 in open-label extension of Phase 2 ALTITUDE-AD trial of sabirnetug.
Expect non-clinical data for EBD candidate in early 2026; Phase 2 topline results in late 2026.
Added biopharma veteran George Golumbeski as Chairman, board expanded to 8 members.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.